Selective targeting of endothelial and perivascular angiocrine ROCK2 treats liver fibrosis.
Hu, Y., Yang, B., Xiao, C., Yang, X., Zhang, H., Yang, P., Du, X., Zhang, G., Liang, B., Bai, N., Zhang, D., Wu, D., Luo, Q., Teng, Y., Chen, Y., Guo, Z., Zhao, C., Ye, T., Chai, D., Qi, X., Zhong, W., Chen, J., Dong, H., Gao, J., He, H., Chang, J., Li, X., Peng, L., Rafii, S., Friedman, S.L., Yi, C., Cai, Y., Zhao, Y., Wang, H., Wang, C., Cao, Z., Ding, B.S.(2026) Cell 189: 2663-2683.e26
- PubMed: 41794026 Search on PubMed
- DOI: https://doi.org/10.1016/j.cell.2026.02.001
- Primary Citation Related Structures: 
9HJQ - PubMed Abstract: 
Liver fibrosis is a prominent pathological process contributing to death from hepatic diseases, including metabolic dysfunction-associated steatohepatitis (MASH). There is limited treatment for liver fibrosis. Here, we find that upregulation of Rho-associated coiled-coil containing kinase 2 (ROCK2) in liver endothelial cells (ECs) and perivascular hepatic stellate cells (HSCs) causes vascular niche dysfunction and triggers pro-fibrotic angiocrine signaling. Based on the vascular druggable target ROCK2, we developed its selective inhibitor showing anti-fibrotic potency in preclinical models and human patients. The ROCK2-selective inhibitor TDI01 restored vascular phenotype and alleviated fibrosis in rodent and minipig MASH models. A phase 1 clinical trial (ChiCTR2200058868) of TDI01 demonstrated its favorable pharmacokinetics and safety in humans. An extended clinical trial (ChiCTR2400082056) showed a trend toward reducing liver fibrosis in five of six patients after TDI01 treatment. Thus, we discover vascular ROCK2 as a pro-fibrotic target, and development of an inhibitor selectively targeting angiocrine ROCK2 may provide a treatment of liver fibrosis in human patients.
- Key Lab of Birth Defects and Related Diseases of Women and Children of MOE, State Key Laboratory of Respiratory Health and Multimorbidity, State Key Laboratory of Biotherapy, Division of Abdominal Tumor Multimodality Treatment, Division of Gastrointestinal Surgery, Department of Radiology, Center of Infectious Diseases, West China Second Hospital, West China School of Basic Medical Sciences & Forensic Medicine, West China Hospital, Sichuan University, Chengdu 610041, China.
Organizational Affiliation: 
















